This bill aims to prohibit pharmaceutical manufacturers from restricting or limiting the distribution of prescription medications to a limited network of out-of-state pharmacies. It introduces a new section to the Arkansas Code, specifically 20-64-105, which outlines legislative findings emphasizing the importance of patient access to prescription drugs and the potential harm caused when local pharmacies cannot obtain necessary medications. The bill highlights the need for transparency and oversight in the distribution of medications, particularly in response to national security threats and natural disasters.

Under the new provisions, pharmaceutical manufacturers must not limit access to their medications for more than three months after a product launch without ensuring similar access to local pharmacies. They are required to maintain an active wholesale distributor permit and must present any requests for restricted networks to the Arkansas State Board of Pharmacy for approval. The bill also stipulates that state government and public plan sponsors will not pay for medications from noncompliant manufacturers unless a temporary waiver is granted, thereby reinforcing the commitment to patient access and safety in Arkansas.